BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024
BioAge Labs announced new preclinical data presentations for azelaprag, their oral APJ agonist, at ObesityWeek 2024. The studies demonstrated that azelaprag enhanced weight loss when combined with various appetite suppressants in obese mice on high-fat diets. As a monotherapy, azelaprag showed protection against excess weight gain, improved body composition, and increased physical activity and energy expenditure. The data supports azelaprag's potential as a novel obesity treatment, both as a standalone therapy and in combination with other medications like semaglutide, tirzepatide, danuglipron, and rimonabant.
BioAge Labs ha annunciato nuove presentazioni di dati preclinici per azelaprag, il loro agonista orale dell'APJ, durante ObesityWeek 2024. Gli studi hanno dimostrato che azelaprag potenzia la perdita di peso quando combinato con vari soppressori dell'appetito in topi obesi in diete ad alto contenuto di grassi. Come monoterapia, azelaprag ha mostrato di proteggere contro l'aumento di peso e ha migliorato la composizione corporea, aumentando l'attività fisica e il dispendio energetico. I dati supportano il potenziale di azelaprag come nuovo trattamento per l'obesità, sia come terapia a sé stante che in combinazione con altri farmaci come semaglutide, tirzepatide, danuglipron e rimonabant.
BioAge Labs anunció nuevas presentaciones de datos preclínicos para azelaprag, su agonista oral de APJ, en ObesityWeek 2024. Los estudios demostraron que azelaprag mejoró la pérdida de peso cuando se combinó con varios supresores del apetito en ratones obesos alimentados con dietas altas en grasas. Como monoterapia, azelaprag mostró protección contra el aumento excesivo de peso, mejoró la composición corporal y aumentó la actividad física y el gasto energético. Los datos respaldan el potencial de azelaprag como un nuevo tratamiento para la obesidad, tanto como terapia independiente como en combinación con otros medicamentos como semaglutida, tirzepatida, danuglipron y rimonabant.
BioAge Labs는 ObesityWeek 2024에서 그들의 구강 APJ 작용제인 azelaprag에 대한 새로운 전임상 데이터 발표를 알렸습니다. 연구는 azelaprag가 고지방 식단을 섭취한 비만 쥐에서 여러가지 식욕 억제제와 결합했을 때 체중 감소를 촉진한다는 것을 보여주었습니다. 단독 치료제로서 azelaprag는 과도한 체중 증가로부터 보호하고 체형을 개선하며 신체 활동과 에너지 소비를 증가시킨 것으로 나타났습니다. 이 데이터는 azelaprag의 독창적인 비만 치료제로서의 가능성을 뒷받침하며, 단독 치료제 및 세마글루타이드, 티르제파타이드, 다누글리프론 및 리모반타이드와 같은 다른 약물과의 조합으로 예상됩니다.
BioAge Labs a annoncé de nouvelles présentations de données précliniques pour azelaprag, leur agoniste oral APJ, lors de ObesityWeek 2024. Les études ont montré qu'azelaprag favorise la perte de poids lorsqu'il est associé à divers coupe-faim chez les souris obèses suivant un régime alimentaire riche en graisses. Comme monothérapie, azelaprag a montré une protection contre le gain de poids excessif, a amélioré la composition corporelle et a augmenté l'activité physique ainsi que la dépense énergétique. Les données soutiennent le potentiel d'azelaprag en tant que nouveau traitement de l'obésité, tant comme thérapie autonome que combinée à d'autres médicaments tels que le sémaglutide, le tirzepatide, le danuglipron et le rimonabant.
BioAge Labs kündigte neue präklinische Datenpräsentationen für azelaprag, ihren oralen APJ-Agonisten, auf der ObesityWeek 2024 an. Die Studien zeigten, dass azelaprag den Gewichtsverlust verstärkte, wenn es mit verschiedenen Appetitzüglern bei fettreichen Diäten bei fetten Mäusen kombiniert wurde. Als Monotherapie zeigte azelaprag Schutz gegen übermäßige Gewichtszunahme, verbesserte die Körperzusammensetzung und steigerte die körperliche Aktivität und den Energieverbrauch. Die Daten unterstützen das Potenzial von azelaprag als neuartige Behandlung der Fettleibigkeit, sowohl als alleinige Therapie als auch in Kombination mit anderen Medikamenten wie Semaglutid, Tirzepatid, Danuglipron und Rimonabant.
- Preclinical data showed enhanced weight loss when azelaprag was combined with multiple appetite suppressants
- Azelaprag demonstrated effectiveness as monotherapy in preventing weight gain
- The drug showed improved body composition and increased physical activity in test subjects
- Results support potential versatility as both standalone and combination therapy
- Results are only from preclinical mouse studies, with no human trial data presented
- Efficacy in humans remains unproven at this stage
Insights
The preclinical data for azelaprag shows promising potential in obesity treatment through two key mechanisms:
- Enhanced weight loss when combined with established treatments like semaglutide and tirzepatide
- Protection against weight gain and improved metabolism as a standalone therapy
While these mouse studies demonstrate positive outcomes, investors should note that preclinical success doesn't guarantee human trial results. The dual-approach strategy - both as a combination therapy and monotherapy - could expand market opportunities if successful. The company's focus on oral administration gives it a potential competitive advantage in the rapidly growing obesity market, where most current treatments require injection.
Two presentations to highlight increased weight loss in obese mice treated with azelaprag in combination with multiple oral appetite suppressants, and significant protection against weight gain with azelaprag monotherapy
RICHMOND, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging, today announced that it will present new preclinical data for its lead product candidate azelaprag, an orally available small molecule agonist of the apelin receptor APJ. The data will be presented at ObesityWeek 2024, held in San Antonio from November 2–6, 2024.
"Our preclinical data highlight the potential of azelaprag as a novel oral therapy for obesity," said Kristen Fortney, Ph.D., CEO and co-founder of BioAge. “Our two presentations provide evidence supporting the ability of BioAge’s azelaprag to enhance weight loss when combined with oral appetite suppression mechanisms, and to protect against excess weight gain and provide metabolic benefits as a monotherapy. These findings support our ongoing clinical development of azelaprag, and our broader mission to develop innovative treatments for metabolic diseases by leveraging insights from human aging biology."
In their two presentations, BioAge CMO and EVP Research Paul Rubin, MD, and VP Translational Aging Biology Yan Wang, PhD, will present data demonstrating that in mice on a high-fat diet, azelaprag increased weight loss and improved body composition in combination with semaglutide, tirzepatide, the oral GLP-1 receptor agonist danuglipron, or the oral CB1 inverse agonist rimonabant. These studies demonstrate the potential of azelaprag to be complementary to a range of oral appetite suppression mechanisms for the treatment of obesity.
Dr. Rubin’s talk will also show that in mice on a high-fat diet, azelaprag monotherapy protected against excess weight gain, improved body composition, and increased physical activity and energy expenditure, reinforcing the metabolic and exercise mimetic benefits of apelin signaling.
Oral presentation: Wednesday, November 6, 2024, 8:45–9:00 am CST
Title: The Apelin Receptor Agonist Azelaprag Reduces Weight Gain & Improves Body Composition in Diet-Induced Obese Mice
Session: Corporate Orals Session 3, room 006
Presenter: Paul Rubin, MD, Chief Medical Officer and EVP Research, BioAge Labs
Poster presentation: Tuesday, November 5, 2024, 2:30 PM CST
Title: The APJ Agonist Azelaprag Improves Weight Loss and Body Composition in DIO Mice on a CB1 Antagonist
Poster number: 628
Presenter: Yan Wang, PhD, VP Translational Aging Biology, BioAge Labs
The visual materials for the presentations will be made available on the BioAge investor website https://ir.bioagelabs.com concurrent with the beginning of their respective sessions.
About BioAge Labs, Inc.
BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. BioAge’s lead product candidate, azelaprag, is an orally available small molecule agonist of APJ that was observed to promote metabolism and prevent muscle atrophy on bed rest in a Phase 1b clinical trial. In mid-2024, BioAge initiated a Phase 2 trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. Azelaprag has potential as an oral regimen to amplify weight loss and improve body composition in patients on obesity therapy with incretin drugs. BioAge is also developing orally available small molecule brain penetrant NLRP3 inhibitors for the treatment of diseases driven by neuroinflammation. BioAge’s preclinical programs, based on novel insights from the company’s discovery platform built on human longevity data, address key pathways in metabolic aging.
Contacts
PR: Chris Patil, media@bioagelabs.com
IR: Elena Liapounova, ir@bioagelabs.com
Partnering: partnering@bioagelabs.com
Web: https://bioagelabs.com
FAQ
What are the key findings of BioAge Labs' azelaprag preclinical studies presented at ObesityWeek 2024?
How does BioAge's azelaprag (BIOA) work for weight loss?
Which medications was azelaprag combined with in BioAge's preclinical studies?
